Meta-analysis finds R1 vascular margin acceptable for HCC but not CLM in minimally invasive liver surgery
Tumor margin choice matters differently for liver cancer types
This meta-analysis of 839 patients undergoing minimally invasive liver surgery found that R1 vascular margin (R1v) hepatectomy yields local …
For liver cancer, leaving a narrow margin is safe. For colorectal metastases, it raises recurrence risk.
Ultrasound-based radiomics nomogram predicts p53 expression in 172 patients with hepatocellular carcinoma
New Ultrasound Tool Predicts Liver Cancer Gene Status Accurately
This cohort study evaluated an ultrasound-based radiomics nomogram integrating variational autoencoder-derived deep features to predict p53 …
A new computer model can read liver ultrasound scans to predict a specific cancer gene mutation that helps guide treatment plans for patient…
Randomized Phase II Trial Evaluates Ociperlimab Plus Tislelizumab and BAT1706 in Advanced Hepatocellular Carcinoma
Adding a new drug did not help liver cancer patients survive longer
This randomized phase II trial enrolled 94 patients with advanced hepatocellular carcinoma. The objective response rate was 37.1% for ociper…
A new drug combination showed promise for advanced liver cancer, but adding a third drug did not improve results.
Review of scRNA-seq applications in non-alcoholic fatty liver disease and hepatocellular carcinoma research
New sequencing tools map liver disease across many species
This narrative review examines the use of single-cell and single-nucleus RNA sequencing in models of non-alcoholic fatty liver disease, fibr…
Scientists used advanced sequencing to study liver disease in humans and animals. This review maps how the disease changes at a cellular lev…
Absence of antiviral therapy and multiple chemotherapeutic agents increase HBV reactivation risk after TACE
No Antiviral Meds Raise Liver Cancer Risks After Chemo
This retrospective cohort study of 168 HBsAg-positive HCC patients undergoing TACE found that absence of prophylactic antiviral therapy (OR …
Many liver cancer patients with hepatitis B face avoidable risks during chemo—because they’re not getting a simple antiviral pill most alrea…
Deep Learning MRI Models Predict Treatment Response in Hepatocellular Carcinoma Following Transarterial Chemoembolization
AI Models Predict Liver Cancer Treatment Response Better Than Standard Scores
This cohort study evaluated AI models using gadoxetic acid–enhanced MRI in 160 patients with Barcelona Clinic Liver Cancer stage A or B hepa…
Artificial intelligence using MRI scans predicted how patients with liver cancer would respond to treatment more accurately than standard cl…
Retrospective Cohort Finds Elevated NLR and PLR Associated with Complications and Survival in Hepatocellular Carcinoma
Post-surgery blood test predicts liver cancer survival better than surgery type alone
This retrospective multicenter cohort study evaluated 74 hepatocellular carcinoma patients undergoing curative hepatectomy or orthotopic liv…
A simple blood test taken months after liver surgery can predict survival better than knowing just how the operation was done.
Systematic review on tertiary lymphoid structures in hepatocellular carcinoma
These immune clusters may predict liver cancer treatment success.
This systematic review synthesizes evidence on tertiary lymphoid structures in hepatocellular carcinoma. It describes their formation, class…
Tiny immune clusters found near liver tumors could help doctors predict if immunotherapy will save lives before treatment starts.
Software validation report shows single biomarkers often outperform panels for breast cancer diagnosis.
New Tool Finds the Tipping Point in Cancer Tests
This software validation report evaluates the TholdStormDX v0.0.1 tool across four diagnostic domains. Key findings indicate that for breast…
A new tool could help doctors decide exactly when a test result means cancer is likely — cutting down on missed cases and false alarms.
Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
Pembrolizumab May Cut Liver Cancer Return After Surgery
This is a Phase 3 randomized controlled trial in 959 participants with hepatocellular carcinoma who had a complete radiological response aft…
After liver surgery, pembrolizumab may help keep hepatocellular carcinoma from returning, offering new hope for patients with complete tumor…
HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
HBV-positive linked to better outcomes in liver cancer triple therapy
This single-center retrospective cohort study evaluated triple therapy with TACE, lenvatinib, and PD-1 inhibitors in 190 patients with initi…
In unresectable liver cancer, triple therapy with TACE, lenvatinib, and PD-1 inhibitors worked better in HBV-positive patients, a small retr…
TACE plus immunotherapy outcomes in intermediate and advanced hepatocellular carcinoma patients
New risk markers found for liver cancer patients getting combined therapy
This cohort study of 243 patients with intermediate and advanced hepatocellular carcinoma identified independent risk factors for tumor prog…
Doctors identified key blood and scan markers that predict how liver cancer progresses in patients receiving a specific combined treatment p…